Trial · NCT06357975

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

NCT06357975, Phase 2, Active not recruiting, National Cancer Institute (NCI); results first posted 2026-03-19

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1). Trials, record NCT06357975. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06357975

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
NCT number: NCT06357975
Status: Active not recruiting
Phases: Phase 2
Enrollment: 44 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Biopsy Procedure, Biospecimen Collection, Crizotinib, Radiologic Examination
First posted: 2024-04-10
Last updated: 2026-03-19
Results first posted: 2026-03-19

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Objective Response Rate (ORR)	Tumor assessments occurred at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration	ORR is defined as the percentage of patients whose tumors have a complete or partial response to treatment among analyzable patients. Objective response is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Details about how to define complete response and partial response can be found in the master protocol. 90% two-sided binomial exact confidence interval is calculated for ORR.
Secondary	6-month Progression Free Survival (PFS)	Assessed at baseline, then every 2 cycles for the first 26 cycles, and every 3 cycles thereafter until disease progression, up to 3 years post registration, from which 6-month PFS rate is determined	Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression. 6 month PFS rate was estimated using the Kaplan-Meier method, which can provide a point estimate for any specific time point.
Secondary	Progression Free Survival	Assessed at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration	PFS was defined as time from treatment start date to date of disease progression or death from any causes, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Please refer to the protocol for detailed definitions of disease progression.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Objective Response Rate (ORR)	Tumor assessments occurred at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration	Eligible, treated and mutation status confirmed	percentage of participants	NUMBER
SECONDARY	6-month Progression Free Survival (PFS)	Assessed at baseline, then every 2 cycles for the first 26 cycles, and every 3 cycles thereafter until disease progression, up to 3 years post registration, from which 6-month PFS rate is determined	Eligible, treated and mutation status confirmed	percentage of participants	NUMBER
SECONDARY	Progression Free Survival	Assessed at baseline, then every 2 cycles for the first 26 cycles and every 3 cycles thereafter until disease progression, up to 3 years post registration	Eligible, treated and mutation status confirmed	months	MEDIAN

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Objective Response Rate (ORR)	Treatment (Crizotinib)	14	90% Confidence Interval 5 to 29.8	percentage of participants
6-month Progression Free Survival (PFS)	Treatment (Crizotinib)	14.3	90% Confidence Interval 5.6 to 26.8	percentage of participants
Progression Free Survival	Treatment (Crizotinib)	3.4	90% Confidence Interval 1.8 to 3.7	months

Source ClinicalTrials.gov

Participant flow5

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Treatment (Crizotinib)	44
Overall Study	Started Protocol Therapy	Treatment (Crizotinib)	40
Overall Study	Eligible, Treated and Mutation Status Confirmed	Treatment (Crizotinib)	28
Overall Study	COMPLETED	Treatment (Crizotinib)	0
Overall Study	NOT COMPLETED	Treatment (Crizotinib)	44

Source ClinicalTrials.gov

Adverse events58

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	Treatment (Crizotinib)	10	40
other	Sinus bradycardia	Cardiac disorders	Treatment (Crizotinib)	2	40
other	Edema limbs	General disorders and administration site conditions	Treatment (Crizotinib)	8	40
other	Fatigue	General disorders and administration site conditions	Treatment (Crizotinib)	8	40
other	Rash acneiform	Skin and subcutaneous tissue disorders	Treatment (Crizotinib)	2	40
other	Abdominal pain	Gastrointestinal disorders	Treatment (Crizotinib)	3	40
other	Constipation	Gastrointestinal disorders	Treatment (Crizotinib)	9	40
other	Diarrhea	Gastrointestinal disorders	Treatment (Crizotinib)	12	40
other	Dyspepsia	Gastrointestinal disorders	Treatment (Crizotinib)	5	40
other	Gastroesophageal reflux disease	Gastrointestinal disorders	Treatment (Crizotinib)	2	40

1 to 10 of 58Source ClinicalTrials.gov

See all 58 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Treatment (Crizotinib)	36	44
Total, other adverse events	Treatment (Crizotinib)	33	40
Total, serious adverse events	Treatment (Crizotinib)	14	40

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
41556942	RESULT

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U10CA180820	ECOG-ACRIN Network Group Operations Center	ODwyer, Peter J; SCHNALL, MITCHELL D.	ECOG-ACRIN MEDICAL RESEARCH FOUNDATION	NATIONAL CANCER INSTITUTE	2014 to 2026

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT06357975

GET https://conductscience.org/api/trials/v1/NCT06357975/events?page=2

API reference For AI assistants